Professor, Ph.D. Supervisor, Mentor of Postdoctoral Research Workstation, Deputy Director of the Clinical Laboratory Department of the First Affiliated Hospital of USTC (Director of the Clinical Laboratory Department of the North District of the First Affiliated Hospital of USTC), High level talents in Anhui Province, Reserve candidates for Academic and Technological leaders in Anhui Province, Core Member of the MOE Key Laboratory for Membraneless Organelles & Cellular Dynamics, Reserve candidate for “Subspecialty Leader” and “Young Technical Backbone” at the First Affiliated Hospital of USTC, Director of the European and American Alumni Association and the Overseas Students Association of USTC, recognized as an “Advanced Individual in the Anti-epidemic Campaign” at USTC. Dr. Wu Quan earned his Ph.D. from USTC in 2009 and pursued further studies at Harvard Medical School/ Boston Children’s Hospital and Morehouse School of Medicine. He has published over 20 SCI-indexed papers in prestigious journals, including Cell Reports, Oncogene, Journal of Biological Chemistry (JBC), and Journal of Proteome Research (JPR). His research has been cited by prominent journals such as Nature, Science, Nature Communications, Science Advances, and Proceedings of the National Academy of Sciences (PNAS). Dr. Wu has received four grants from the National Natural Science Foundation of China and one from the Anhui Provincial Natural Science Foundation. His work has also been recognized with one second prize and two third prizes of Anhui Provincial Science and Technology Awards.
Education and Work Experience
- 2004–2009: Ph.D, University of Science and Technology of China (Successive postgraduate and doctoral programs)
- 2007–2008: Morehouse School of Medicine, USA
- 2017–2018: Harvard Medical School/ Boston Children's Hospital, USA
- 2019–Present: Professor, The First Affiliated Hospital of USTC
- 2013–2019: Associate Professor, The First Affiliated Hospital of USTC
Academic Achievements and Impact
1. Histone Modifications and Lung Cancer Research:
Revealed the Modification rules and functional interconnections of histone acetylation, ubiquitination, crotonylation, and dihydroxyisobutyrylation in lung cancer cells, mapping these modifications. Conducted in-depth studies on the functions of novel modifications of histones and non-histones within cells, discovering their crucial role in regulating cell fate and function. This work laid the foundation for elucidating the pathogenesis, innovating diagnosis and treatment strategies, and drug development for lung cancer.
2. Chemotherapy Resistance in Malignant Tumors:
Explored the clinical foundations and mechanisms for reversing chemotherapy resistance in malignant tumors, screening out molecular markers for evaluating reversal of drug resistance. This research applied to the treatment of malignant tumors in clinical practice, providing new therapeutic avenues for cancer patients.
3. Membrane Protein Research:
Investigated the composition of cell membrane proteins associated with the endoplasmic reticulum membrane complex (EMC), revealing EMC’s regulatory role in membrane protein synthesis and integration. This work offers new insights for the studies of membrane protein and targets for membrane protein-related diseases.
Ongoing Projects (Limited to Principal Investigator)
- Anhui Province Special Support Plan of Health Innovation Leading Talent Project, Anhui Provincial Government, 500,000 CNY, 2021-01 to 2025-12
- The Roles and Mechanism of Ubiquitination of ALKBH4 Regulated by DTX2 Mediating the Initiation and Progression of Lung Adenocarcinoma (82272971), National Natural Science Foundation General Project, 520,000 CNY, 2023-01 to 2026-12
Main Research Directions (Enrollment Specialties) and Content
Clinical Medicine
1. Clinical Laboratory Diagnostics, Oncology, Internal Medicine (Oncology), Surgery (Oncology)
- Study of the biological functions and mechanisms of protein post-translational modification pathways and regulatory enzymes intumor development and progression.
- Research on the biological functions and mechanisms of non-coding RNA in tumor progression.
- Investigation of membrane protein synthesis and membrane integration rules and their roles in tumors.
- Research and screening of tumor-related biomarkers and personalized medicine.
Representative Papers (Last Five Years)
1. He A#, Tian S#, Kopper O, Horan DJ, Chen P, Bronson RT, Sheng R, Wu H, Sui L, Zhou K, Tao L, Wu Q, Huang Y, Shen Z, Han S, Chen X, Chen H, He X, Robling AG, Jin R, Clevers H, Xiang D*, Li Z*, Dong M*.Targeted inhibition of Wnt signaling with a Clostridioides difficile toxin B fragment suppresses breast cancer tumor growth. PLoS Biol. 2023 Nov 9;21(11):e3002353。
2. Feng X#, Bu F#, Huang L#, Xu W, Wang W*, Wu Q*.Preclinical evidence of the effect of quercetin on diabetic nephropathy: A meta-analysis of animal studies.Eur J Pharmacol. 15;921:174868(2022).
3. Guo C#, Liu Q#, Zong D#, Zhang W, Zuo Z, Yu Q, Sha Q, Zhu L, Gao X, Fang J, Tao J, Wu Q, Li X, Qu K*.Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus.Cell Rep. 2022 Nov 8;41(6):111606(2022).
4. Shuai Kong#, Lu Ding#, Chenkun Fan#, Yun Li#, Chi Wang Ke Wang Weilong Xu Xuanming Shi, Quan Wu*, Fengsong Wang*. Global analysis of lysine acetylome reveals the potential role of CCL18 in non‐small cell lung cancer. Proteomics. 21(7-8):e2000144(2021).
5. Songhai Tian#, Quan Wu#, Bo Zhou, Mei Yuk Choi, Bo Ding, Wei Yang, Min Dong*.Proteomic analysis identifies membrane proteins dependent on the ER membrane protein complex. Cell Reports. 28, 2517–2526(2019) .
6. Pengcheng Du#, Pengfei Cai#, Beibei Huang, Chen Jiang, Quan Wu*, Bin Li*, Kun Qu*.SMAtool reveals sequences and structural principles of protein-RNA interaction. Biochem Biophys Res Commun. 525, 53-56(2020).
7.Liu X#, Xu L#, Li J, Yao PY, Wang W, Ismail H, Wang H, Liao B, Yang Z, Ward T, Ruan K, Zhang J, Wu Q, He P, Ding X, Wang D, Fu C, Dou Z, Yan F, Wang W*, Liu X*, Yao X.Mitotic motor CENP-E cooperates with PRC1 in temporal control of central spindle assembly. J Mol Cell Biol. 12(8):654-665(2020).
8.Chi Wang, Yun Li, Li Ke, Lejie Cao, Pingsheng Fan, Zhiwei Wu, Quan Wu*. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Cancer. 10(4): 885–892(2019).
Contact Information
Email: powerwu1@ustc.edu.cn
Phone: 0551-62283574